The Effect of Dipeptidyl Peptidase-4 Inhibition on GLP-1 Induced Insulin Secretion and Glucose Turnover During Mild Stable Hyperglycemia in Young and Old Normal Volunteers
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Insulin Release Rate and Hepatic Glucose Release
研究概览
简要总结
This research is being done to evaluate the effect of glucagon-like peptide-1 (GLP-1, a naturally occurring hormone) on insulin release and to examine whether there is extra insulin release when GLP-1 is not allowed to be rapidly inactivated.
详细描述
The purpose of the present proposal is to 1) examine the role of dipeptidyl peptidase (DPP-4) inhibition on insulin release during a hyperglycemic clamp while GLP-1 is being infused and, 2) further elucidate the role of the metabolite of GLP-1, that is GLP-1 9-36 amide (GLP-1m). During stable and very reproducible elevated plasma glucose levels the effect of increased active incretin levels with DPP-4 inhibitors should result in increased plasma insulin levels. Therefore the aim of this protocol is to document whether plasma insulin levels are increased following GLP-1 infusion in the presence or absence of DPP-4 inhibitors. Additionally, the investigators have shown that some improvement in glucose homeostasis during GLP-1 administration is due in part to the metabolite of GLP-1, i.e. GLP-1 (9-36) amide (GLP-1m). Therefore, the investigators will also test the role of the latter by infusing GLP-1m when the volunteers are being treated with DPP-4 inhibitors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Health Services Research
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 21 Years 至 75 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Hct level of at least 34% for women and 36% for men
- •Women of non-bearing potential and women of childbearing potential using adequate contraception
- •Serum creatine level of less than 1.7 mg/dl
- •Four groups:
- •Age 21-45 (BMI between 18.50-24.99) & (BMI between 30-35)
- •Age greater than 65 years (BMI between 18.50-24.99) & (BMI between 30-35)
排除标准
- •Pregnant and/or lactating females
- •Women of childbearing potential not willing to use adequate contraception
- •Hct below inclusion criteria
- •Serum creatine level greater than 1.8 mg/dl
- •Age less than 21 and age between 46-64
- •Diabetes mellitus
- •BMI less than 18 and BMI greater than 35
研究组 & 干预措施
Placebo
干预措施: Placebo (Drug)
Januvia
干预措施: Januvia (Drug)
结局指标
主要结局
Insulin Release Rate and Hepatic Glucose Release
时间窗: One year
次要结局
- Peripheral Glucose Utilization and Peripheral Glucagon Release(one year)
